|
SI1545613T1
(sl)
|
2002-07-31 |
2011-11-30 |
Seattle Genetics Inc |
Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
ES2673822T3
(es)
*
|
2006-07-18 |
2018-06-25 |
Sanofi |
Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
|
|
PL2631248T3
(pl)
|
2007-06-15 |
2018-06-29 |
Medigene Ag |
Leczenie nowotworów z użyciem specyficznego przeciwciała anty-L1
|
|
NZ583318A
(en)
|
2007-07-16 |
2012-07-27 |
Genentech Inc |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
DK2474557T3
(da)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
|
HRP20170407T1
(hr)
*
|
2007-08-30 |
2017-05-05 |
Daiichi Sankyo Company, Limited |
Anti-epha2 anitijelo
|
|
JP2011509079A
(ja)
|
2007-12-24 |
2011-03-24 |
オックスフォード ビオトヘラペウトイクス エルティーディー． |
エフリンａ型受容体１０タンパク質
|
|
SG187517A1
(en)
|
2008-01-31 |
2013-02-28 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
US20100009390A1
(en)
*
|
2008-05-09 |
2010-01-14 |
The Regents Of The University Of California |
Mutant antibodies with high affinity for egfr
|
|
US20100008978A1
(en)
*
|
2008-05-09 |
2010-01-14 |
The Regents Of The University Of California |
Nanoparticles effective for internalization into cells
|
|
WO2011109440A1
(en)
|
2010-03-01 |
2011-09-09 |
Caris Life Sciences Luxembourg Holdings |
Biomarkers for theranostics
|
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
|
AU2011213609B2
(en)
*
|
2010-02-08 |
2016-11-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
|
|
WO2011127219A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings |
Circulating biomarkers for disease
|
|
EP4234698A3
(en)
|
2010-05-06 |
2023-11-08 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
|
DK3323830T3
(da)
|
2010-06-19 |
2023-09-25 |
Memorial Sloan Kettering Cancer Center |
Anti-gd2 antibodies
|
|
MX349662B
(es)
*
|
2010-07-22 |
2017-08-08 |
Univ California |
Anticuerpos de antigenos antitumorales y metodos de uso.
|
|
NZ607337A
(en)
|
2010-08-20 |
2015-06-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
JP6105481B2
(ja)
|
2010-12-06 |
2017-03-29 |
シアトル ジェネティクス，インコーポレーテッド |
Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用
|
|
WO2012118547A1
(en)
|
2010-12-08 |
2012-09-07 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
|
KR102023496B1
(ko)
*
|
2011-04-21 |
2019-09-20 |
시애틀 지네틱스, 인크. |
신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
|
|
HUE045348T2
(hu)
*
|
2011-05-08 |
2019-12-30 |
Legochem Biosciences Inc |
Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
|
|
JP6180425B2
(ja)
|
2011-11-23 |
2017-08-23 |
メディミューン，エルエルシー |
Ｈｅｒ３に特異的な結合分子及びそれらの使用
|
|
AU2012349735B2
(en)
|
2011-12-05 |
2016-05-19 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
KR20140103135A
(ko)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
|
EP2855520B1
(en)
|
2012-06-04 |
2018-09-26 |
Novartis AG |
Site-specific labeling methods and molecules produced thereby
|
|
CN104507537A
(zh)
*
|
2012-07-13 |
2015-04-08 |
宾夕法尼亚大学董事会 |
用于调节car t细胞的组合物和方法
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
CN104837502B
(zh)
|
2012-10-12 |
2018-08-10 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
KR102447350B1
(ko)
|
2013-02-08 |
2022-09-23 |
노파르티스 아게 |
면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
|
CA2902026C
(en)
*
|
2013-03-13 |
2023-08-29 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
EP2970479B1
(en)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antibodies against notch 3
|
|
NZ710929A
(en)
|
2013-03-15 |
2018-02-23 |
Novartis Ag |
Antibody drug conjugates
|
|
CN105705165B
(zh)
|
2013-03-15 |
2020-04-24 |
纪念斯隆-凯特琳癌症中心 |
高亲和力抗gd2抗体
|
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
CN105828841A
(zh)
*
|
2013-11-04 |
2016-08-03 |
辉瑞大药厂 |
抗-efna4抗体-药物缀合物
|
|
CN105899539B
(zh)
|
2014-01-10 |
2021-11-09 |
博笛生物科技有限公司 |
用于免疫疗法的化合物和组合物
|
|
CA2940451A1
(en)
|
2014-03-12 |
2015-09-17 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
US9777070B2
(en)
|
2014-04-30 |
2017-10-03 |
Pfizer Inc |
Anti-PTK7 antibody-drug conjugates
|
|
EP3166976B2
(en)
|
2014-07-09 |
2026-04-08 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
US10550195B2
(en)
|
2014-07-11 |
2020-02-04 |
The Regents Of The University Of California |
Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
|
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
|
KR20170040249A
(ko)
|
2014-08-12 |
2017-04-12 |
노파르티스 아게 |
항-cdh6 항체 약물 접합체
|
|
CN112587672A
(zh)
*
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
|
MX388698B
(es)
|
2014-09-30 |
2025-03-20 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
|
|
MX2017004580A
(es)
*
|
2014-10-10 |
2017-06-27 |
Pfizer |
Combinaciones de auristatina sinergica.
|
|
JP6882978B2
(ja)
|
2014-10-29 |
2021-06-02 |
バイスクルアールディー・リミテッド |
Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
|
|
WO2016075670A1
(en)
|
2014-11-14 |
2016-05-19 |
Novartis Ag |
Antibody drug conjugates
|
|
EP3221351B1
(en)
*
|
2014-11-19 |
2024-11-13 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of epha2
|
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
CN109862919A
(zh)
|
2016-10-11 |
2019-06-07 |
免疫医疗有限公司 |
抗体-药物缀合物联合免疫介导的治疗剂
|
|
KR20240000650A
(ko)
|
2016-10-19 |
2024-01-02 |
인벤라 인코포레이티드 |
항체 구조물
|
|
EP3559039A1
(en)
|
2016-12-22 |
2019-10-30 |
Università Degli Studi Magna Graecia Catanzaro |
A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
CN118515666A
(zh)
|
2017-04-27 |
2024-08-20 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
IL312120B2
(en)
|
2017-06-23 |
2025-06-01 |
Birdie Biopharmaceuticals Inc |
Pharmaceutical compositions
|
|
JP7301757B2
(ja)
|
2017-06-26 |
2023-07-03 |
バイスクルアールディー・リミテッド |
検出可能部分を持つ二環式ペプチドリガンドおよびその使用
|
|
US11530413B2
(en)
|
2017-07-21 |
2022-12-20 |
Novartis Ag |
Compositions and methods to treat cancer
|
|
CN111183147B
(zh)
|
2017-08-04 |
2024-07-05 |
拜斯科技术开发有限公司 |
Cd137特异性的双环肽配体
|
|
WO2019075097A1
(en)
*
|
2017-10-11 |
2019-04-18 |
Board Of Regents, The University Of Texas System |
PD-L1 HUMAN ANTIBODIES AND METHODS OF USE
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
WO2019091449A1
(zh)
*
|
2017-11-10 |
2019-05-16 |
江苏恒瑞医药股份有限公司 |
Cd96抗体、其抗原结合片段及医药用途
|
|
JP2021514953A
(ja)
|
2018-02-23 |
2021-06-17 |
バイスクルテクス・リミテッド |
多量体二環式ペプチドリガンド
|
|
WO2019182867A1
(en)
|
2018-03-23 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
|
CN119101158A
(zh)
|
2018-03-23 |
2024-12-10 |
得克萨斯州大学系统董事会 |
人pd-l2抗体及其使用方法
|
|
EP3768726B1
(en)
|
2018-03-23 |
2024-10-30 |
Board of Regents, The University of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
JOP20200268A1
(ar)
|
2018-06-01 |
2020-10-26 |
Eisai R&D Man Co Ltd |
تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
|
|
WO2019234136A1
(en)
|
2018-06-05 |
2019-12-12 |
King's College London |
Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
|
|
WO2019234694A2
(en)
*
|
2018-06-07 |
2019-12-12 |
Magenta Therapeutics, Inc. |
Therapeutic methods using antibody drug conjugates (adcs)
|
|
GB201810316D0
(en)
*
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
WO2020076849A1
(en)
|
2018-10-11 |
2020-04-16 |
The Scripps Research Institute |
Antibody compounds with reactive arginine and related antibody drug conjugates
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
PE20211473A1
(es)
|
2018-12-13 |
2021-08-05 |
Eisai Randd Man Co Ltd |
Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso
|
|
JP2022514618A
(ja)
|
2018-12-21 |
2022-02-14 |
バイスクルテクス・リミテッド |
Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
|
|
JP7607564B2
(ja)
|
2018-12-21 |
2024-12-27 |
ノバルティス アーゲー |
Ｐｍｅｌ１７に対する抗体及びその結合体
|
|
US12551567B2
(en)
|
2018-12-21 |
2026-02-17 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for PD-L1
|
|
GB201900529D0
(en)
|
2019-01-15 |
2019-03-06 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for CD38
|
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
IL300248A
(en)
|
2020-08-03 |
2023-03-01 |
Bicycletx Ltd |
peptide-based linkers
|
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
CA3200858A1
(en)
|
2020-11-24 |
2022-06-02 |
Novartis Ag |
Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
US12162945B2
(en)
|
2021-03-05 |
2024-12-10 |
Immunome, Inc. |
EPHA2 antibodies
|
|
CA3235132A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
KR20230060546A
(ko)
|
2021-10-22 |
2023-05-04 |
상트네어바이오사이언스 주식회사 |
두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
AU2022441090A1
(en)
|
2022-02-17 |
2024-08-22 |
Novelty Nobility Inc. |
Antibody-drug conjugate.
|
|
IL317102A
(en)
|
2022-05-20 |
2025-01-01 |
Novartis Ag |
EPHA2 BCL-XL inhibitor antibody-drug conjugates and methods of using them
|
|
CN120787162A
(zh)
|
2022-05-20 |
2025-10-14 |
诺华股份有限公司 |
抗肿瘤化合物的抗体-药物缀合物及其使用方法
|
|
AU2024234194A1
(en)
|
2023-03-10 |
2025-08-07 |
Novartis Ag |
Panras inhibitor antibody-drug conjugates and methods of use thereof
|
|
WO2024219894A1
(ko)
|
2023-04-21 |
2024-10-24 |
상트네어바이오사이언스 주식회사 |
두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
|
|
WO2026069006A1
(en)
|
2024-09-30 |
2026-04-02 |
Sunrise Oncology (Hong Kong) Limited |
Ras inhibitor antibody-drug conjugates and methods of use thereof
|